Abstract
Background: Dapsone is helpful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3).Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by Dapsone should be responsible for its observed preventive treatment effects, functioning as a competitor against Pandemic viral inflammasome.Methods: We compared Hansen's disease (HD) patients with viral respiratory diseases (VRD) after prescribing Dapsone to standard treatment from 2005 to 2020. Results: The 3022 VRD participants who received the dapsone intervention (M = 201, SD = 34) compared to the 3961 VRD participants in the control group (M = 264, SD = 84) demonstrated significantly better peak flow scores, t(28) = -2.7, p = .01. It demonstrated significantly more prevalences of VRD in the DDS unprescribed group. Conclusion: This study is theoretical clinical data to warrant a pilot study with Dapsone for deteriorating leprosy patients at Pandemic.